The HIV-1 matrix protein p17 activates the transcription factors c-Myc and CREB in human B cells

New Microbiologica

Volumn 33, Issue 1, 2010, Pages 13-24

  Li, Song ^a   Bozzo, Luisa ^a   Wu, Zhibin ^a   Lu, Wuyuan ^a   Romerio, Fabio ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

Atds associated lymphoma; C myc; CREB; Hiv 1 p17

Indexed keywords

CD19 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MYC PROTEIN; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;

ARTICLE; B LYMPHOCYTE; CELL STRAIN HEPG2; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PHOSPHORYLATION; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANTIGENS, CD19; B-LYMPHOCYTES; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEP G2 CELLS; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77950199793     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. ALIMONTI J.B., BALL XB., FOWKE K.R. (2003). Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and ATDS. J. Gen. Virol 84, 1649-1661.
2. ALBINI A., BARILLARI G., BENELU R., GALLO R.C., ENSOLI B. (1995). Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc. Natl Acad. Sci. USA. 92, 4838-4842.
3. ALBINI A., SOLDI R, GIUNCIUGLIO D., GIRAUDO E., BENELLI R., PRIMO L., NOONAN D., SALIO M., CAMUSSI G., ROCKL W., BUSSOLINO F. (1996). The angiogenesis induced by HTV-I tat protein is mediated by the Flk-1/KDR receptor on vascular endodielial cells. Nat. Med. 2, 1371-1375.
4. AOKI Y., TOSATO G. (2003). Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr. Drug. Targets. Infect. Disord. 3, 115-128.
5. AOKI Y., TOSATO G. (2004). HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood. 104, 810-814.
6. AOKI Y., TOSATO G. (2004). Neoplastic conditions in the context of HIV-I infection. Curr. HIV. Res. 2, 343-349.
7. BARILLARI G., GENDELMAN R., GALLO R.C, ENSOLI B. (1993). The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc. Natl Acad. Sci. USA 90, 7941-7945.\
8. BUKRINSKAYA A.G., VORKUNOVA G.K., TENTSOV Y.Y. (1992). HIV-1 matrix protein p17 resides in cell nuclei in association with genomic RNA. AIDS Res. Hum. Retroviruses. 8, 1795-1801.
9. BUKRINSKY M.I., HAGGERTY S., DEMPSEY M.P., SHAROVA N., ADZHUBEL A., SPITZ L., LEWIS P., GOLDFARB D., EMERMAN M., STEVENSON M. (1993). A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature. 365, 666-669.
10. BURATTI E., TISMINETZKY S.G., D'AGARO P., BARALLE F.E. (1997). A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence TEEE. J. Virol 71, 2457-2462.
11. CARBONE A., GLOGHINI A. (2005). AIDS-related lymphomas: from pathogenesis to pathology. Br. J. Haematol 130, 662-670.
12. CHARGELEGUE D., STANLEY C.M., OTOOLE CM., COLVIN B.T., STEWARD M.W. (1995). The affinity of IgG antibodies to gag p24 and p.7 in HIV-1-infected patients correlates with disease progression. Clin. Exp. Immunol. 99, 175-181.
13. DE FRANCESCO M.A., BARONIO M., FIORENTINI S., SIGNORINI C., BONFANTI C., POIESI C., POPOVIC M., GRASSI M., GARRAFA E., BOZZO L., LEWIS G.K., LICENZIATI S., GALLO R.C., CARUSO A. (2002). HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc. Natl. Acad. Sci. USA. 99, 9972-9977.
14. DE FRANCESCO M.A., CARUSO A., FALLACARA F., CANARIS A.D., DIMA F., POIESI C., LICENZIATI S., CORULU M., MARTINELLI E, FIORENTINI S., TURANO A. (1998). HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor. AIDS. 12, 245-252.
15. ENSOLI B., BARILLARI G., SALAHUDDIN S.Z., GALLO R.C., WONG-STAAL E (1990). Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 345, 84-86.
16. FACKE M., JANETZKO A., SHOEMAN R.L., KRÄUSSUCH H.G. (1993). A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to die endoplasmic reticulum. J. Virol 67, 4972-4980.
17. FIORENTINI S., MARINI E., CARACCIOLO S., CARUSO A. (2006). Functions of the HIV-1 matrix protein p17. New Microbiol 29, 1-10.
18. FREED E.O. (1998). HIV-1 gag proteins: diverse functions in the virus life cycle. Virology. 251, 1-15.
19. FRISCH M., BIGGAR R.J., ENGELS E.A., GOEDERT J.J., AIDS-CANCER MATCH REGISTRY STUDY GROUP. (2001). Association of cancer with AIDS-related immunosuppression in adults. JAMA 285, 1736-1745.
20. GAIDANO G., CAPELLO D., CARBONE A. (2000). The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis. Semin. Oncol. 27, 431-441.
21. GALLAY P., SWINGLER S., SONG J., BUSHMAN F., TRONO D. (1995). HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell. 83, 569-576.
22. GRANDORI C., MAC J., SIËBELT F., AYER D.E., EISENMAN R.N. (1996). Myc-Max heterodimers activate a DEAD box gene and interact with multiple E boxrelated sites in vivo. EMBO J. 15, 4344-4357.
23. Gu W., ČECHOVA K., TASSI V., DALLA-FAVERA R. (1993). Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. Proc. Natl Acad. Sci USA. 90, 2935-2939.
24. HECHT J.L., ASTER J.C. (2000). Molecular biology of Burkitts lymphoma. J. Clin. Oncol. 18, 3707-3721.
25. HERBEIN G., MAHLKNECHT U., BATLIWALLA E., GREGERSEN P., PAPPAS T., BUTLER J., O'BRIEN W.A., VERDIN E. (1998). Apoptosis of CD8+ X cells is mediated by macrophages through interaction of HTV gp120 with chemokine receptor CXCR4. Nature. 395,189-194.
26. HOLM G.H., ZHANG C., GORRY P.R., PEDEN K., SCHOLS D., DE CLERCQ E., GABUZDA D. (2004). Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. J Virol. 78, 4541-4551.
27. JEKLE A., KEPPLER O.T., DE CLERCQ E., SCHOLS D., WEINSTEIN M., GOLDSMITH M.A. (2003). In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J. Virol 77, 5846-5854.
28. KARN J., WATSON J.V, LOWE A.D., GREEN S.M., VEDECKIS W. (1989). Regulation of cell cycle duration by cmyc levels. Oncogene. 4, 773-787.
29. LAFRENEE R.M., WAHL L.M., EPSTEIN J.S., YAMADA K.M., DHAWAN S. (1997). Activation of monocytes by HIVTat treatment is mediated by cytokine expression. J. Immunol 159, 4077-4083.
30. LANGE J.M., DE WOLF E, KRONE W.J., DANNER S.A., COUTINHO R.A., GOUDSMIT J. (1987). Decline of antibody reactivity to outer viral core protein p 17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. AIDS. 1, 155-159.
31. LITTLE R.F., GUTIERREZ M., JAFFE E.S., PAU A., HORNE M., WILSON W. (2001). HIV-associated non-Hodgkin lymphoma: incidence, presentation, and progno-sis. JAMA. 285, 1880-1885.
32. MAI S., JALAVA A. (1994). c-Myc binds to 5' flanking sequence motifs of the dihydrofolate reductase gene in cellular extracts: role in proliferation. Nucleic Acids Res. 22, 2264-2273.
33. MARCU K.B., BOSSONE S.A., PATEL AJ. (1992). Myc function and regulation. Annu. Rev. Biochem. 61, 809-860.
34. MARINI E., TIBERIO L., CARACCIOLO S., Tosn G., GUZMAN C.A., SCHIAFFONATI L., FIORENTINI S., CARUSO A. (2008). HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: role of transcriptional factor AP-1. Cell. Microbiol 10, 655-666.
35. NAYLOR RH., NAYLOR C.W., BADAMCHIAN M., WADA S., GOLDSTEIN A.L., WANG S.S., SUN D.K., THORNTON A.H., SARIN P.S. (1987). Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30. Proc. Natl. Acad. SCi. USA. 84, 2951-2955.
36. NEKHAI S, JEANG K.T. (2006). Transcriptional and posttranscriptional regulation of HIV-1 gene expression: role of cellular factors for Tat and Rev. Future Microbiol. 1, 417-426.
37. PACE C.N., VAJDOS F., FEE L., GRIMSLEY G., GRAY X (1995). How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4, 2411-2423.
38. PAPSIDERO L.D., SHEU M., RUSCETTI EW. (1989). Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J. Virol 63, 267-272.
39. POPOVIC M., TENNER-RACZ K, PELSER C., STELLBRINK H.J., VAN LUNZEN J., LEWIS G., KALYANARAMAN V.S., GALLO R.C., RACZ P. (2005). Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA. 102, 14807-14812.
40. SÁNCHEZ-BEATO M., SÁNCHEZ-AGUILERA A., PIRIS M.A. (2003). Cell cycle deregulation in B-cell lymphomas. Blood. 101, 1220-1235.
41. SHIM H., DOLDE C., LEWIS B.C., Wu C.S., DANG G., JUNGMANN R.A., DALLA-FAVERA R., DANG C.V. (1997). c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. SCi. USA. 94, 6658-6663.
42. SPEARMAN P., WANG J.J., VANDER HEYDEN N., RATNER L. (1994). Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J. Virol. 68, 3232-3242.
43. VITALE M., CARUSO A., DE FRANCESCO M.A., RODELLA L., BOZZO L., GARRAFA E., GRASSI M., GOBBI G., CACCHIOLI A., FIORENTINI S. (2003). HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases Their abuity to secrete proinflammatory cytokines. Br. J. Haematol. 120, 337-343.
44. WHITE P.C., SHORE A.M., CLEMENT M., MCLAREN J., SOEIRO I., LAM, E.W., BRENNAN P. (2006). Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. Oncogene. 25, 2170-2180.
45. WILSON B.E., MOCHON E., BOXER L.M. (1996). Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell. Biol. 16, 5546-5556.
46. Wu Z., ALEXANDRATOS J., ERICKSEN B., LUBKOWSKI J., GALLO R.C., Lu W. (2004). Total chemical synthesis of N-myristoylated HIV-1 matrix protein p17: structural and mechanistic implications of p17 myristoylation. Proc. Natl Acad. Sci. USA. 101, 11587-11592.
47. YUAN X., YU X., LEE T.H., ESSEX M. (1993). Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J. Virol 67, 63876394.
48. ZAGURY D., LACHGAR A., CHAMS V., FALL L.S., BERNARD J., ZAGURY J.F., BIZZINI B., GRINGERI A., SANTAGOSTINO E., RAPPAPORT J., FELDMAN M., BURNY A., GALLO R.C. (1998). Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in ATDS. Proc. Natl Acad. Sci. U. S.A. 95, 3851-3856.
49. ZHANG CY, WU Y.L., BOXER L.M. (2002). Impaired proliferation and survival of activated B cells in transgenic mice that express a dominant-negative cAMPresponse element-binding protein transcription factor in B cells. J. Biol. Chem. 277, 48359-48365.